AMRX

Amneal Pharmaceuticals, Inc. Class A Common Stock

14.09

USD

AMRX Earnings Reports

Positive Surprise Ratio

AMRX beat 26 of 40 last estimates.

65%

Next Report

Date of Next Report

Feb 27, 2026

Estimate for Q4 25 (Revenue/ EPS)

$824.05M

$0.18

Implied change from Q3 25 (Revenue/ EPS)

+5.04%

+5.88%

Implied change from Q4 24 (Revenue/ EPS)

+12.80%

+50.00%

Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Oct 30, 2025, AMRX reported earnings of 0.17 USD per share (EPS) for Q3 25, beating the estimate of 0.14 USD, resulting in a 21.17% surprise. Revenue reached 784.51 million, compared to an expected 787.76 million, with a -0.41% difference. The market reacted with a -4.12% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of 0.18 USD, with revenue projected to reach 824.05 million USD, implying an increase of 5.88% EPS, and increase of 5.04% in Revenue from the last quarter.

FAQ

What were Amneal Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.17, beating estimates by 21.17%, and revenue of $784.51M, -0.41% below expectations.

How did the market react to Amneal Pharmaceuticals, Inc. Class A Common Stock's Q3 2025 earnings?

The stock price moved down -4.12%, changed from $10.43 before the earnings release to $10.00 the day after.

When is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Feb 27, 2026.

What are the forecasts for Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report?

Based on 7 analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.18 and revenue of $824.05M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.